Skip to main content
Premium Trial:

Request an Annual Quote

Transkaryotic Therapies Licenses Cell Genesys Protein Patents

NEW YORK, June 10-Transkaryotic Therapies has licensed a set of protein patents from Cell Genesys, the company said today.


The license, which is exclusive, covers some of Cell Genesys' work in gene activation.


Under the agreement, Transkaryotic will pay $26 million in up-front license fees, including $11 million cash and $15 million in common stock. Cell Genesys may also receive milestone payments, but not royalties.


Transkaryotic Therapies is a publicly held company based in Cambridge, Mass. It is developing therapeutics based on protein replacement.


Cell Genesys is based in Foster City, Calif.


For further details, see the company press release.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.